Your browser doesn't support javascript.
loading
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis.
Kolijn, P Martijn; Hosnijeh, Fatemeh Saberi; Späth, Florentin; Hengeveld, Paul J; Agathangelidis, Andreas; Saleh, Manal; Casabonne, Delphine; Benavente, Yolanda; Jerkeman, Mats; Agudo, Antonio; Barricarte, Aurelio; Besson, Caroline; Sánchez, Maria-Jose; Chirlaque, María-Dolores; Masala, Giovanna; Sacerdote, Carlotta; Grioni, Sara; Schulze, Matthias B; Nieters, Alexandra; Engelfriet, Peter; Hultdin, Magnus; McKay, James D; Vermeulen, Roel C H; Langerak, Anton W.
Afiliación
  • Kolijn PM; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, The Netherlands.
  • Hosnijeh FS; Division of Environmental Epidemiology and Veterinary Public Health, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
  • Späth F; Division of Environmental Epidemiology and Veterinary Public Health, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
  • Hengeveld PJ; Department of Radiation Sciences, Oncology, Cancer Center, Department of Hematology.
  • Agathangelidis A; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, The Netherlands.
  • Saleh M; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Casabonne D; Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
  • Benavente Y; Division of Environmental Epidemiology and Veterinary Public Health, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
  • Jerkeman M; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública, Madrid, Spain.
  • Agudo A; Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Cancer Epidemiology Research Programme, Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, Hospitalet De Llobregat, Barcelona, Spain.
  • Barricarte A; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública, Madrid, Spain.
  • Besson C; Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Cancer Epidemiology Research Programme, Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, Hospitalet De Llobregat, Barcelona, Spain.
  • Sánchez MJ; Division of Oncology, Lund University, Lund, Sweden.
  • Chirlaque MD; Department of Oncology, Skane University Hospital, Lund, Sweden.
  • Masala G; Unit of Nutrition and Cancer, Epidemiology, Public Health, Cancer Prevention, and Palliative Care Program, Bellvitge Biomedical Research Institute, Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, Hospitalet De Llobregat, Barcelona, Spain.
  • Sacerdote C; Navarra Public Health Institute, Navarra Institute for Health Research, Pamplona, Spain.
  • Grioni S; Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Schulze MB; Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), French Institute of Health and Medical Research (INSERM), Équipe "Exposome et Hérédité", Centre de Recherche en épidémiologie et Santé des populations (CESP), Villejuif, France.
  • Nieters A; Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.
  • Engelfriet P; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
  • Hultdin M; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública, Madrid, Spain.
  • McKay JD; Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Vermeulen RCH; Department of Epidemiology, Regional Health Council, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia University, Murcia, Spain.
  • Langerak AW; Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
Blood ; 139(10): 1557-1563, 2022 03 10.
Article en En | MEDLINE | ID: mdl-34662377
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfocitosis Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfocitosis Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos